BackgroundHigh-dose isoproterenol infusion is a useful provocative maneuver to elicit triggers of atrial fibrillation (AF) during ablation. We evaluated whether the use of isoproterenol infusion to elicit triggers of AF after ablation is associated with differential outcomes.MethodsWe performed a retrospective study of all patients who underwent de novo radiofrequency catheter ablation of AF enrolled in the University of California, San Diego AF Ablation Registry. The primary outcome was freedom from atrial arrhythmias on or off antiarrhythmic drugs (AAD).ResultsOf 314 patients undergoing AF ablation, 235 (74.8%) received isoproterenol while 79 (25.2%) did not. Among those who received isoproterenol, 11 (4.7%) had additional triggers identified. There were no statistically significant differences in procedure time (p= 0.432), antiarrhythmic drug use (p= 0.289), procedural complications (p= 0.279), recurrences of atrial arrhythmias on or off AAD [adjusted hazard ratio (AHR) 0.92 (95% CI 0.58–1.46);p= 0.714], all-cause hospitalizations [AHR 1.00 (95% CI 0.60–1.67);p= 0.986], or all-cause mortality [AHR 0.14 (95% CI 0.01–3.52);p= 0.229] between groups.ConclusionsIn this registry analysis, use of isoproterenol is safe but was not associated with a reduction in recurrence of atrial arrhythmias.